Damora Therapeutics, Inc. (DMRA): R&D Expense
$26.88M
Year ended 2025-12-31
$74.05M
Trailing 12 months to 2026-06-30
-17.7%
3-year compound annual growth
+1.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $26.88M | +320.1% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $6.40M | -73.1% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $23.77M | -50.7% | 2025-03-19, From 2023-01-01 |
| 2022-12-31 | $48.21M | +25.2% | 2024-03-08, From 2022-01-01 |
| 2021-12-31 | $38.49M | +56.3% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $24.63M | +24.8% | 2022-02-17, From 2020-01-01 |
| 2019-12-31 | $19.74M | n/a | 2021-03-29, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | 2025-12-31 | $26.88M | +320.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $32.78M | -3.8% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $64.81M | +15.9% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $147.17M | -16.9% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $12.43M | -25.5% |
| Perspective Therapeutics, Inc. (CATX) | 2025-12-31 | $84.22M | +102.3% |
| Savara Inc (SVRA) | 2025-12-31 | $81.40M | +4.3% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $112.21M | -42.5% |
Compare DMRA, NATR, PHAT, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗